• THE NEXT

    GENERATION OF IMMUNOTHERAPY

    Salspera is developing its platform of novel microbial therapies to tackle a wide range of solid tumor cancers.

  • A leading company in microbial immunotherapy.

    Salspera is a private, clinical stage company developing its platform of novel microbial immunotherapies in solid tumor indications.

    Novel Therapy

    This innovative approach to immunotherapy has been shown to be safe and effective in human clinical trials and through years of published animal studies.

    Clinical Stage

    Salspera’s lead candidate, Saltikva®, is an oral immunotherapy that is currently in a Phase 2 study in patients with metastatic pancreatic cancer

    Immunotherapy Platform

    Salspera is developing its novel bacterial-based immunotherapy platform in additional solid tumor indications

  • It's time for cancer therapy to work with the body, not against it.

    Salspera is a clinical-stage biotechnology company committed to developing novel therapies for solid tumor cancers. The company has a platform of microbial immunotherapies that have the potential to address a range of solid tumor cancers where unmet medical need is high. We believe microbial immunotherapies could be used to create a new category of medicines with significant potential to improve the lives of patients.

  • A Phase I, Dose Escalation, Single Dose Trial of Oral Attenuated Salmonella typhimurium Containing Human IL-2 in Patients With Metastatic Gastrointestinal Cancers

    Oral Saltikva resulted in a significant increase in NK and NK-T cells with no toxicity or adverse events observed in phase I safety trial.

  • Orally Administered Multiple Dose Saltikva (Salmonella-IL2) in Conjunction with Folfirinox in a Patient with Stage IV Pancreatic Cancer: A Case Report

    Orally administered Saltikva resulted in a complete absence of metabolic tumor activity by PET scan, regression of metastatic tumor burden, and a strong NK cell mediated immune response in stage IV pancreatic cancer. Patient is currently in month 20 (compared to median survival of 11.1 months) and has not experienced any toxicity from the experimental treatment.

  • SALTIKVA

    Genetically engineered microbial therapy to release human IL-2 within the tumor microenvironment

    Oral and Safe

    Saltikva is orally administered and is non-toxic with no observed adverse events to date

    Targeted

    Saltikva seeks and colonizes solid tumors and metastases with 10:000:1 ratio over normal tissues

    Immunostimulatory

    Saltikva results in NK Cell activation following IL-2 expression; no systemic toxicity since IL-2 is only expressed in tumor and metastases

  • PIPELINE

    Our robust pipeline has development programs spanning multiple indications.

     

     

    Our Phase 2 study in stage IV metastatic pancreatic cancer was initiated in October 2020. Saltikva is being tested in combination with current standard of care which consists of FOLFIRINOX or Gemcitabine, both chemotherapeutic regimens which patients are selected for depending on their comorbidity profile. This disease has a prevalence of roughly 225K patients in major markets (US/EU) and its prognosis is 11.1-month median survival (MS) for patients taking FOLFIRINOX and 6.8-month MS for patients taking gemcitabine.

     

    Learn more about our clinical trial

  • Strategic Partnership Interests

    Contact us at bd@salspera.com

    Partner US/EU and/or RoW Commercialization of Saltikva® in Stage IV Metastatic Pancreatic Cancer

    • Partners with companies that have existing solid tumor salesforces and commercialization expertise in major (US/EU) and RoW markets

    Partner Saltikva® in Additional Solid Tumor Indications

    • Partnerships for Saltikva® development in indications not currently being explored (i.e. GI tract cancers)
    • Partnership for Saltikva® as a combination therapy with other clinical stage or approved solid tumor assets

    Partner Other Salspera Constructs in Additional Solid Tumor Indications

    • Partnering of Salspera pipeline for development of additional solid tumor therapies
    • Combination therapy with other solid tumor assets

    Partner Salspera Construct with Other Company's Biologic to Improve its Delivery Profile

    • Use genetically engineered microbial immunotherapy to express partner’s biologic drug for superior administration, safety, and efficacy
  • CONTACT US

    Salspera, LLC
     
    3510 Hopkins Place N.
    Oakdale, MN 55128